Engineered immune cells take on incurable blood cancer
NCT ID NCT07689058
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial investigates a personalized cell therapy called CAR-T, which reprograms a patient's own immune cells to recognize and attack a protein (BCMA) on multiple myeloma cells. The study enrolls 10 adults whose cancer has returned or become resistant after at least three prior treatments. The main goal is to see if the therapy is safe and can be reliably manufactured, while also checking for early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cells targeting BCMA
- What this could lead to
- If successful, this could offer a new treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase pilot study with only 10 participants, so results may not apply broadly. CAR-T therapy carries risks of serious side effects like cytokine release syndrome and neurological issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University of Medical Sciences, Clinical Trial Unit
RECRUITINGRawalpindi, Punjab Province, 46000, Pakistan
-
National University of Medical Sciences, Clinical Trial Unit
RECRUITINGRawalpindi, Punjab Province, 46000, Pakistan
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New CAR T-Cell therapy targets Hard-to-Treat myeloma
- New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
- Why do blood cancer patients skip home care? new study aims to find out.
- Could a simple shot replace hospital stays for myeloma patients?
- New hope for hard-to-treat myeloma: drug duo targets genetic weak spot
- New shot aims to wipe out myeloma in patients out of options